Gazyva Wins First FDA Approval for Membranous Nephropathy, but Rituximab Was Skipped as Comparator
Gazyva Wins First FDA Approval for Membranous Nephropathy, but Rituximab Was Skipped as Comparator Tech Times
What this means for you
Approval is not the same as coverage. A newly approved treatment usually spends a year being denied by insurers before it is routinely paid for, and that gap is where the appeal process matters.